Trial Profile
Ancillary Observational Study of Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2022
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Dasatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 10 Oct 2022 Planned End Date changed from 1 Mar 2023 to 1 May 2024.
- 10 Oct 2022 Planned primary completion date changed from 1 Mar 2023 to 1 May 2024.
- 10 Oct 2022 Status changed from not yet recruiting to recruiting.